Lambert-Eaton myasthenic syndrome


Also found in: Dictionary, Thesaurus, Acronyms, Wikipedia.
Related to Lambert-Eaton myasthenic syndrome: myasthenia gravis

Lam·bert-Ea·ton myasthenic syn·drome (LEMS),

(lam'bert ē'tŏn),
a generalized disorder of neuromuscular transmission caused by a defect in the release of acetylcholine quanta from the presynaptic nerve terminals; often associated with small cell carcinoma of the lung, particularly in elderly men with a long history of cigarette smoking. In contrast to myasthenia gravis, weakness tends to affect solely axial muscles, girdle muscles, and less often the limb muscles; autonomic disturbances, for example, dry mouth and impotence, are common; the deep tendon reflexes are unelicitable; on motor conduction studies, responses on initial stimulation are quite low in amplitude, but they show marked posttetanic facilitation after a few seconds of exercise. Lambert-Eaton syndrome is due to loss of voltage-sensitive calcium channels located on the presynaptic motor nerve terminal. See: myasthenic syndrome.

Lambert-Eaton myasthenic syndrome

(lăm′bərt-ēt′n)
n.
An autoimmune disorder that affects neuromuscular transmission and is usually associated with lung cancer, characterized by weakness of muscles especially in the limbs.

Lambert-Eaton myasthenic syndrome

(lam'bert-et'on)
[Edward Howard Lambert, U.S. physiologist, 1915–2003; Lee McKendree Eaton, U.S. physician, 1905–1958]
An autoimmune syndrome in which weakness of the proximal muscles (e.g., around the shoulder and the hip girdle), diminished reflexes, and autonomic dysfunction are found. The syndrome is often associated with small cell carcinoma of the lung or other malignancies. Its cause is a unique antibody against presynaptic calcium channels.
Synonym: Eaton-Lambert syndrome
References in periodicals archive ?
Net proceeds from the proposed offering will be utilised by the company for the continuing development of Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome, pre-commercialisation activities relating to Firdapse, continuing development of CPP-115 as well as for general corporate purposes.
Specialist pharmaceutical company Catalyst Pharmaceutical Partners Inc (NasdaqCM:CPRX) said on Tuesday that it will continue with its planned ongoing pivotal Phase III clinical trial in the US and Europe evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) based on the review of safety and clinical data.
M2 EQUITYBITES-April 2, 2014-Catalyst Pharmaceutical Partners concludes patient enrollment in pivotal Phase 3 trial of Firdapse in Lambert-Eaton Myasthenic Syndrome patients